文献速递中毒与环境急症消化、代谢与肾脏急症

更安全阿片类药物供应项目中药物转用的视角

Perspectives on Diversion of Medications From Safer Opioid Supply Programs.
PubMed 文献 · JAMA Netw Open · 2024-12-02
一句话结论定性研究显示,更安全供应项目的药物转用是一个从无转用到偶发分享、丢失到出售全部处方的谱系,原因复杂,监测与惩罚措施不太可能缓解,作者认为宜通过扩大药物选择与配套社会支持来应对。

该研究于2021年在加拿大安大略省4个更安全供应项目中对21名提供者(医生、执业护士和 allied health professionals)和52名患者进行定性访谈和社会人口学问卷,分析药物转用情况。结果显示,转用行为呈谱系分布:从无转用,到偶发分享和丢失,再到出售全部处方剂量(被认为罕见且易于发现)。多数患者报告服用全部或大部分处方药物,很少分享或出售。转用的主要原因包括:与亲密伴侣和朋友出于同情分享以管理戒断和过量风险;出售或交易以满足自身未满足的物质使用需求(如高阿片耐受);以及因贫困、无家可归及相关脆弱性导致的药物丢失、被盗和胁迫。项目采用非惩罚性尿药筛查和患者自我报告监测药物使用,发现转用时提供者使用非评判性对话了解患者需求并制定缓解策略。作者认为,转用最好通过扩大药物选择以更好匹配患者多样化的物质使用需求和高耐受,并配合全方位社会支持来应对。

要点

  • 转用被描述为一个谱系:从无转用,到偶发分享和丢失,再到出售全部处方剂量(被认为罕见且易于发现)。
  • 多数患者报告服用全部或大部分处方药物,很少分享或出售;但参与者共同提到人们可能出于多种原因分享、交易和/或出售部分药物。
  • 转用最突出的原因包括:与亲密伴侣和朋友出于同情分享以管理戒断和过量风险;出售或交易以满足自身未满足的物质使用需求(如高阿片耐受);因贫困、无家可归及相关脆弱性导致的药物丢失、被盗和胁迫。
  • 项目使用非惩罚性尿药筛查和患者自我报告监测药物使用;发现转用时,提供者使用非评判性对话了解患者需求并制定缓解策略,包括调整剂量和药物以更好匹配需求、纳入符合条件的亲密伴侣、制定安全计划以减轻被盗和胁迫的脆弱性。
  • 作者认为,监测和惩罚措施不太可能缓解转用;转用最好通过扩大药物选择以更好匹配患者多样化的物质使用需求和高耐受,并配合全方位社会支持来应对。

适用人群与场景

  • 加拿大安大略省4个更安全供应项目的患者(n=52)和提供者(n=21,包括医生、执业护士和 allied health professionals)。

处置流程与药物剂量

  • 项目使用非惩罚性尿药筛查实践和患者自我报告来监测药物使用。
  • 当发现转用时,提供者使用非评判性对话了解患者需求并制定缓解策略,包括改变处方剂量和药物以更好匹配患者需求、纳入符合条件的亲密伴侣、制定安全计划以减轻被盗和胁迫的脆弱性。

研究设计与关键结果

  • 研究类型为定性访谈和社会人口学问卷,于2021年在加拿大安大略省4个更安全供应项目中进行;52名患者中29名(55.8%)为男性、23名(44.2%)为女性,1名(1.9%)为黑人、9名(17.3%)为原住民、1名(1.9%)为拉丁裔、41名(78.8%)为白人,平均(SD)年龄46.5(9.6)岁;21名提供者中6名(28.6%)为男性、13名(61.9%)为女性、2名(9.5%)为非二元性别,平均(SD)年龄37.6(7.6)岁。
  • 参与者将转用描述为一个谱系,从无转用,到偶发药物分享和丢失,再到出售全部处方剂量(被认为罕见且易于发现)。
  • 多数患者报告服用全部或大部分处方药物,很少分享或出售剂量;但提供者和患者参与者共同提到人们可能出于多种原因与其他阿片使用者分享、交易和/或出售部分药物。
  • 转用的最突出原因包括:(1)与亲密伴侣和朋友出于同情分享以管理戒断和过量风险;(2)出售或交易药物以满足自身未满足的物质使用需求(如高阿片耐受);(3)因贫困、无家可归及相关脆弱性导致的药物丢失、被盗和胁迫。
  • 当发现转用时,提供者描述使用非评判性对话了解患者需求并制定缓解策略,包括改变处方剂量和药物以更好匹配患者需求、纳入符合条件的亲密伴侣、制定安全计划以减轻被盗和胁迫的脆弱性。

证据类型、等级与局限

  • 证据类型:定性研究(访谈和问卷)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,监测和惩罚措施不太可能缓解转用,转用最好通过扩大药物选择以更好匹配患者多样化的物质使用需求和高耐受,并配合全方位社会支持来应对。
  • 原文描述项目使用非惩罚性尿药筛查和患者自我报告监测药物使用,并在发现转用时使用非评判性对话和缓解策略,但未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Safer supply programs were implemented in Canada to provide pharmaceutical-grade alternatives to the toxic unregulated drug supply. While research shows clinical benefits and reduced overdose mortality among safer supply patients, medication diversion remains a concern.

OBJECTIVE: To examine provider (prescribing clinicians and allied health professionals) and patient perspectives on diversion of opioids prescribed in safer supply programs.

DESIGN, SETTING, AND PARTICIPANTS: In 2021, qualitative interviews and sociodemographic questionnaires were conducted with patients and providers across 4 safer supply programs in Ontario, Canada. Interviews with 21 providers (physicians, nurse practitioners, and allied health professionals) and 52 patients examined experiences implementing safer supply or receiving care. Initial data analysis was conducted from December 2021 to March 2022, and the subanalysis focused on diversion was conducted from December 2023 to March 2024.

EXPOSURES: Participation in safer supply program as a patient or provider.

MAIN OUTCOMES AND MEASURES: Data about diversion were coded, extracted, and thematically analyzed.

RESULTS: Of 52 patient participants, 29 (55.8%) were men and 23 (44.2%) were women; 1 was Black (1.9%), 9 (17.3%) were Indigenous, 1 was Latino (1.9%), and 41 (78.8%) were White; and the mean (SD) age was 46.5 (9.6) years. Of 21 provider participants, 6 (28.6%) were men, 13 (61.9%) were women, and 2 (9.5%) were nonbinary; and the mean (SD) age was 37.6 (7.6) years. Participants characterized diversion as a spectrum ranging from no diversion, to occasional medication sharing and loss, to selling all prescribed doses of safer supply (considered rare and easy to detect). Most patients reported they consumed all or most of their prescribed medications and rarely shared or sold their doses. However, providers and patient participants shared that people might share, trade, and/or sell some of their medications with other opioid-using people for multiple reasons. Most prominent reasons for diversion were (1) compassionate sharing with intimate partners and friends to manage withdrawal and overdose risk; (2) selling or trading medications to address their own unmet substance use needs (eg, high opioid tolerance); and (3) medication loss due to poverty, homelessness, and associated vulnerabilities to theft and coercion. Programs used nonpunitive urine drug screening practices and patient self-report to monitor medication use. When diversion was identified, providers described using nonjudgmental conversations to understand patients' needs and develop mitigation strategies that addressed underlying reasons for diversion, including changing doses and medications prescribed to better match patients' needs, enrolling eligible intimate partners, and developing safety plans to mitigate vulnerabilities to theft and coercion.

CONCLUSIONS AND RELEVANCE: Diversion encompasses a wide spectrum of practices (selling, sharing, and loss of medications), and occurs for complex reasons that surveillance and punitive measures are unlikely to mitigate. Diversion may be best addressed by expanding medication options to better match patients' diverse substance use needs and high tolerance, alongside wraparound social supports.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Olding M, Rudzinski K, Schmidt R, et al. Perspectives on Diversion of Medications From Safer Opioid Supply Programs. JAMA Netw Open. 2024. PMID: 39693066. doi:10.1001/jamanetworkopen.2024.51988

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。